Asitri Dashboard Search Clinical Trials
The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.
Saved Searches
Choose Search
Basic Search
Clinical Trials Search Results
Search History:
Count: 94
Selected: 0
| NCT ID | Title | ||
|---|---|---|---|
| NCT04607772 | Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL) | ||
| NCT02227251 | Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) | ||
| NCT02314247 | Efficacy and Safety Study of Selinexor in Relapsed or Refractory Peripheral T-cell Lymphoma or Cutaneous T-cell Lymphoma | ||
| NCT02402764 | Phase 2 Trial of Selinexor (KPT-330) for Metastatic Triple Negative Breast Cancer (TNBC) | ||
| NCT04843579 | Treatment of Selinexor in Combination With Clarithromycin, Pomalidomide and Dexamethasone for Relapsed Refractory Multiple Myeloma Patients | ||
| NCT04421378 | A Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastoma | ||
| NCT02367690 | Study of Safety, Tolerability, and Pharmacokinetics of Topical Selinexor (KPT-330) Diabetic Foot Ulcer (DFU) Patients | ||
| NCT04519476 | Selinexor Treatment for Multiple Myeloma Patients Who Are Refractory to Lenalidomide-containing Therapy. | ||
| NCT03732703 | Myeloma-Developing Regimens Using Genomics (MyDRUG) | ||
| NCT04717700 | Selinexor With Alternating Bortezomib or Lenalidomide Plus Dexamethasone in TIE Newly Diagnosed MM Patients | ||
| NCT02436707 | Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma | ||
| NCT02431351 | Efficacy & Safety Study of KPT-330 in Erythropoietin-Refractory Lower-Risk Myelodysplastic Syndrome Patients | ||
| NCT04661137 | A Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple Myeloma | ||
| NCT04925193 | Personalized Selinexor-based Therapy for Relapsed/Refractory Multiple Myeloma | ||
| NCT05983276 | Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standard Chemotherapy in Ovarian Cancer | ||
| NCT04914845 | KPT-9274 in Patients With Relapsed and Refractory Acute Myeloid Leukemia | ||
| NCT03095612 | Phase 1/2 Trial of Selinexor (KPT-330) With Docetaxel for Non-small Cell Lung Cancer (NSCLC) | ||
| NCT04562870 | A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants With Previously Treated Myelofibrosis | ||
| NCT02212561 | Selinexor With Fludarabine and Cytarabine for Treatment of Refractory or Relapsed Leukemia or Myelodysplastic Syndrome | ||
| NCT02403310 | A Study of Selinexor in Combination With Daunorubicin and Cytarabine for Untreated AML | ||
| NCT02351505 | Selinexor in Treating Patients With Relapsed Small Cell Lung Cancer | ||
| NCT02213133 | Selinexor Treatment of Advanced Relapsed/Refractory Squamous Cell Carcinomas | ||
| NCT04782687 | Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma | ||
| NCT07479979 | Study of Selinexor With Carfilzomib, Isatuximab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma | ||
| NCT01607905 | Safety Study of KPT-330 (Selinexor) in Patients With Advanced or Metastatic Solid Tumor Cancer | ||
| NCT02741388 | A Phase Ib Study of Oral Selinexor in Adult Patients With Relapsed/Refractory B-cell Lymphoma Receiving R-DHAOx or R-GDP | ||
| NCT02606461 | Selinexor in Advanced Liposarcoma | ||
| NCT03627403 | Selinexor in Myelofibrosis Refractory or Intolerant to JAK1/2 Inhibitors | ||
| NCT02186834 | Selinexor (KPT-330) and Liposomal Doxorubicin For Relapsed and Refractory Multiple Myeloma | ||
| NCT02249091 | A Phase II Study of Selinexor Plus Cytarabine and Idarubicin in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) | ||
| NCT03955783 | Venetoclax and Selinexor in Treating Patients with Relapsed or Refractory High Risk Hematologic Malignancies | ||
| NCT05980806 | A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia | ||
| NCT03071276 | Selinexor in Combination With Fludarabine and Cytarabine in Patients With Refractory or Relapsed Acute Myeloid Leukemia | ||
| NCT02137356 | Selinexor Combined With Standard Chemoradiation as Neoadjuvant Treatment in Locally Advanced Rectal Cancer | ||
| NCT02384850 | Phase 1 Trial To Evaluate mFOLFOX6 With Selinexor In Patients With Metastatic Colorectal Cancer | ||
| NCT02416908 | Study of CLAG + Selinexor in Relapsed or Refractory Acute Myeloid Leukemia | ||
| NCT02138786 | Selinexor in Initial or Refractory and/or Relapsed Richter's Transformation | ||
| NCT01896505 | A Phase I Trial to Assess the Effects of Food and Formulation on PK of KPT-330 in Patients With Sarcoma | ||
| NCT07215832 | Karyopharm Expanded Access Program for Selinexor | ||
| NCT04349098 | Evaluation of Activity and Safety of Oral Selinexor in Participants With Severe COVID-19 Infection | ||
| NCT02336815 | Selinexor Treatment of Refractory Myeloma | ||
| NCT03191981 | Pembrolizumab Cyclophosphamide and Lenalidomide for Patients With Relapsed Multiple Myeloma | ||
| NCT05170789 | Elotuzumab, Selinexor, and Dexamethasone for Relapsed Refractory Multiple Myeloma | ||
| NCT02299518 | Selinexor and Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | ||
| NCT02146833 | SHIP (Selinexor in Hormone Insensitive Prostate Cancer) | ||
| NCT02078349 | Phase I Study of KPT330 in Asian Patients | ||
| NCT01986348 | Study Evaluating the Efficacy and Safety of Selinexor (KPT-330) in Participants With Recurrent Gliomas | ||
| NCT04984330 | Selinexor for Treatment of Light Chain Amyloidosis With Relapsed/Refractory Disease | ||
| NCT01607892 | Safety Study of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients With Advanced Hematological Cancer | ||
| NCT02628704 | Selinexor, Carfilzomib, and Dexamethasone Versus Placebo, Carfilzomib, and Dexamethasone in Multiple Myeloma |
